Eli Lilly & Co. – Capital Expenditure

Quarterly charts & data from official filings

Timeframe

Capital expenditure

Capital expenditureTable view

Earnings release date
Capital expenditure
Earnings release date:30 Apr. 26
Capital expenditure:
2,326,000,000 $-8.7%
Earnings release date:04 Feb. 26
Capital expenditure:
2,546,700,000 $+22.0%
Earnings release date:30 Oct. 25
Capital expenditure:
2,087,700,000 $+23.0%
Earnings release date:07 Aug. 25
Capital expenditure:
1,697,100,000 $+12.4%
Earnings release date:01 May. 25
Capital expenditure:
1,509,500,000 $+0.9%
Earnings release date:06 Feb. 25
Capital expenditure:
1,496,000,000 $+10.8%
Earnings release date:30 Oct. 24
Capital expenditure:
1,350,700,000 $+10.3%
Earnings release date:08 Aug. 24
Capital expenditure:
1,224,800,000 $+24.2%
Earnings release date:30 Apr. 24
Capital expenditure:
986,300,000 $-7.9%
Earnings release date:06 Feb. 24
Capital expenditure:
1,070,600,000 $+10.3%
Earnings release date:02 Nov. 23
Capital expenditure:
970,300,000 $+31.4%
Earnings release date:08 Aug. 23
Capital expenditure:
738,200,000 $+10.4%
Earnings release date:27 Apr. 23
Capital expenditure:
668,500,000 $+33.5%
Earnings release date:02 Feb. 23
Capital expenditure:
500,700,000 $-18.9%
Earnings release date:01 Nov. 22
Capital expenditure:
617,200,000 $+66.4%
Earnings release date:04 Aug. 22
Capital expenditure:
371,000,000 $

Revenue by segment

Revenue by segmentTable view

Earnings release date
Cardiometabolic Health
Oncology
Immunology
Neuroscience
Other
Total
Earnings release date:30 Apr. 26
Cardiometabolic Health:
15,760,000,000 $+8.7%
Oncology:
2,268,000,000 $-13.0%
Immunology:
1,203,000,000 $-21.9%
Neuroscience:
382,000,000 $-16.8%
Other:
187,000,000 $-2.3%
Total:
19,800,000,000 $+2.6%
Earnings release date:04 Feb. 26
Cardiometabolic Health:
14,492,100,000 $+10.0%
Oncology:
2,607,300,000 $+8.3%
Immunology:
1,541,000,000 $+13.1%
Neuroscience:
459,200,000 $+45.5%
Other:
191,400,000 $-43.2%
Total:
19,291,000,000 $+9.6%
Earnings release date:30 Oct. 25
Cardiometabolic Health:
13,177,900,000 $+16.2%
Oncology:
2,407,600,000 $-0.2%
Immunology:
1,362,400,000 $+8.5%
Neuroscience:
315,700,000 $-8.2%
Other:
337,200,000 $+67.3%
Total:
17,600,800,000 $+13.1%
Earnings release date:07 Aug. 25
Cardiometabolic Health:
11,342,900,000 $+23.2%
Oncology:
2,413,600,000 $+23.9%
Immunology:
1,255,600,000 $+15.4%
Neuroscience:
344,000,000 $+26.4%
Other:
201,500,000 $-5.4%
Total:
15,557,600,000 $+22.2%
Earnings release date:01 May. 25
Cardiometabolic Health:
9,208,100,000 $+1.1%
Oncology:
1,947,500,000 $-23.7%
Immunology:
1,088,000,000 $-15.7%
Neuroscience:
272,100,000 $-30.8%
Other:
212,900,000 $+11.6%
Total:
12,728,600,000 $-5.9%
Earnings release date:06 Feb. 25
Cardiometabolic Health:
9,106,300,000 $+22.9%
Oncology:
2,551,900,000 $+14.3%
Immunology:
1,290,800,000 $+8.9%
Neuroscience:
393,000,000 $+11.7%
Other:
190,700,000 $-27.4%
Total:
13,532,700,000 $+18.3%
Earnings release date:30 Oct. 24
Cardiometabolic Health:
7,407,000,000 $-1.4%
Oncology:
2,231,800,000 $+3.4%
Immunology:
1,185,700,000 $+9.5%
Neuroscience:
351,800,000 $+3.6%
Other:
262,800,000 $+26.6%
Total:
11,439,100,000 $+1.2%
Earnings release date:08 Aug. 24
Cardiometabolic Health:
7,514,600,000 $+36.8%
Oncology:
2,158,700,000 $+19.3%
Immunology:
1,082,400,000 $+29.8%
Neuroscience:
339,500,000 $-12.7%
Other:
207,600,000 $-14.2%
Total:
11,302,800,000 $+28.9%
Earnings release date:30 Apr. 24
Cardiometabolic Health:
5,493,000,000 $-4.4%
Oncology:
1,810,000,000 $-3.9%
Immunology:
834,000,000 $-24.5%
Neuroscience:
389,100,000 $+7.3%
Other:
241,900,000 $-5.6%
Total:
8,768,000,000 $-6.3%
Earnings release date:06 Feb. 24
Cardiometabolic Health:
5,745,900,000 $+21.7%
Oncology:
1,884,200,000 $+7.8%
Immunology:
1,104,300,000 $+11.9%
Neuroscience:
362,700,000 $-79.5%
Other:
256,200,000 $-7.2%
Total:
9,353,300,000 $-1.5%
Earnings release date:02 Nov. 23
Cardiometabolic Health:
4,720,400,000 $-5.8%
Oncology:
1,747,100,000 $+4.6%
Immunology:
986,900,000 $+6.3%
Neuroscience:
1,768,100,000 $+356.6%
Other:
276,100,000 $-12.2%
Total:
9,498,600,000 $+14.3%
Earnings release date:08 Aug. 23
Cardiometabolic Health:
5,010,900,000 $+19.6%
Oncology:
1,671,000,000 $+23.2%
Immunology:
928,500,000 $+19.4%
Neuroscience:
387,200,000 $+7.4%
Other:
314,600,000 $+14.3%
Total:
8,312,200,000 $+19.4%
Earnings release date:27 Apr. 23
Cardiometabolic Health:
4,190,400,000 $+5.4%
Oncology:
1,356,000,000 $-17.9%
Immunology:
777,800,000 $-16.7%
Neuroscience:
360,500,000 $-6.5%
Other:
275,300,000 $-22.7%
Total:
6,960,000,000 $-4.7%
Earnings release date:02 Feb. 23
Cardiometabolic Health:
3,975,800,000 $+8.6%
Oncology:
1,651,200,000 $+27.7%
Immunology:
933,600,000 $+7.8%
Neuroscience:
385,400,000 $+3.3%
Other:
356,000,000 $-52.3%
Total:
7,302,000,000 $+5.2%
Earnings release date:01 Nov. 22
Cardiometabolic Health:
3,662,600,000 $+6.5%
Oncology:
1,293,300,000 $-5.5%
Immunology:
866,400,000 $+8.8%
Neuroscience:
373,200,000 $-4.3%
Other:
746,000,000 $+50.8%
Total:
6,941,500,000 $+7.0%
Earnings release date:04 Aug. 22
Cardiometabolic Health:
3,438,200,000 $
Oncology:
1,368,700,000 $
Immunology:
796,500,000 $
Neuroscience:
389,900,000 $
Other:
494,700,000 $
Total:
6,488,000,000 $

Revenue by product line

Revenue by product lineTable view

Earnings release date
Mounjaro
Zepbound
Trulicity
Jardiance
Other cardiometabolic health
Verzenio
Other oncology
Taltz
Other immunology
Neuroscience
Other
Humalog
Humulin
Basaglar
Baqsimi
Alimta
Cyramza
Erbitux
Tyvyt
Olumiant
Cymbalta
Emgality
Zyprexa
Other neuroscience
COVID-19 antibodies
Forteo
Cialis
Total
Earnings release date:30 Apr. 26
Mounjaro:
8,662,000,000 $+16.9%
Zepbound:
4,160,000,000 $-2.4%
Trulicity:
919,000,000 $-11.4%
Jardiance:
1,114,000,000 $+45.1%
Other cardiometabolic health:
905,000,000 $-11.0%
Verzenio:
1,302,000,000 $-18.9%
Other oncology:
966,000,000 $-3.7%
Taltz:
733,000,000 $-30.3%
Other immunology:
470,000,000 $-3.9%
Neuroscience:
382,000,000 $-16.8%
Other:
187,000,000 $-2.3%
Humalog:
–
Humulin:
–
Basaglar:
–
Baqsimi:
–
Alimta:
–
Cyramza:
–
Erbitux:
–
Tyvyt:
–
Olumiant:
–
Cymbalta:
–
Emgality:
–
Zyprexa:
–
Other neuroscience:
–
COVID-19 antibodies:
–
Forteo:
–
Cialis:
–
Total:
19,800,000,000 $+2.6%
Earnings release date:04 Feb. 26
Mounjaro:
7,409,200,000 $+13.7%
Zepbound:
4,260,600,000 $+18.7%
Trulicity:
1,036,800,000 $-1.4%
Jardiance:
767,600,000 $-20.0%
Other cardiometabolic health:
1,016,900,000 $-4.4%
Verzenio:
1,604,600,000 $+9.1%
Other oncology:
1,002,700,000 $+7.0%
Taltz:
1,052,000,000 $+16.7%
Other immunology:
489,000,000 $+6.1%
Neuroscience:
459,200,000 $+45.5%
Other:
191,400,000 $-43.2%
Humalog:
–
Humulin:
–
Basaglar:
–
Baqsimi:
–
Alimta:
–
Cyramza:
–
Erbitux:
–
Tyvyt:
–
Olumiant:
–
Cymbalta:
–
Emgality:
–
Zyprexa:
–
Other neuroscience:
–
COVID-19 antibodies:
–
Forteo:
–
Cialis:
–
Total:
19,290,000,000 $+9.6%
Earnings release date:30 Oct. 25
Mounjaro:
6,515,100,000 $+25.3%
Zepbound:
3,588,100,000 $+6.1%
Trulicity:
1,051,800,000 $-3.7%
Jardiance:
959,000,000 $+39.0%
Other cardiometabolic health:
1,063,900,000 $+8.5%
Verzenio:
1,470,200,000 $-1.3%
Other oncology:
937,400,000 $+1.4%
Taltz:
901,500,000 $+6.4%
Other immunology:
460,900,000 $+13.0%
Neuroscience:
315,700,000 $-8.2%
Other:
337,200,000 $+67.3%
Humalog:
–
Humulin:
–
Basaglar:
–
Baqsimi:
–
Alimta:
–
Cyramza:
–
Erbitux:
–
Tyvyt:
–
Olumiant:
–
Cymbalta:
–
Emgality:
–
Zyprexa:
–
Other neuroscience:
–
COVID-19 antibodies:
–
Forteo:
–
Cialis:
–
Total:
17,600,800,000 $+13.1%
Earnings release date:07 Aug. 25
Mounjaro:
5,198,900,000 $+35.3%
Zepbound:
3,381,400,000 $+46.3%
Trulicity:
1,092,200,000 $-0.3%
Jardiance:
690,000,000 $-32.0%
Other cardiometabolic health:
980,400,000 $+3.8%
Verzenio:
1,489,300,000 $+28.5%
Other oncology:
924,300,000 $+17.2%
Taltz:
847,600,000 $+11.2%
Other immunology:
408,000,000 $+25.1%
Neuroscience:
344,000,000 $+26.4%
Other:
201,500,000 $-5.4%
Humalog:
–
Humulin:
–
Basaglar:
–
Baqsimi:
–
Alimta:
–
Cyramza:
–
Erbitux:
–
Tyvyt:
–
Olumiant:
–
Cymbalta:
–
Emgality:
–
Zyprexa:
–
Other neuroscience:
–
COVID-19 antibodies:
–
Forteo:
–
Cialis:
–
Total:
15,557,600,000 $+22.2%
Earnings release date:01 May. 25
Mounjaro:
3,841,800,000 $+8.8%
Zepbound:
2,311,900,000 $+21.2%
Trulicity:
1,095,200,000 $-12.4%
Jardiance:
1,014,400,000 $-15.4%
Other cardiometabolic health:
944,800,000 $+575.3%
Verzenio:
1,158,900,000 $-25.5%
Other oncology:
788,600,000 $+84.6%
Taltz:
761,900,000 $-20.0%
Other immunology:
326,100,000 $+321.9%
Neuroscience:
272,100,000 $
Other:
212,900,000 $+11.6%
Humalog:
–
Humulin:
–
Basaglar:
–
Baqsimi:
–
Alimta:
–
Cyramza:
–
Erbitux:
–
Tyvyt:
–
Olumiant:
–
Cymbalta:
–
Emgality:
–
Zyprexa:
–
Other neuroscience:
–
COVID-19 antibodies:
–
Forteo:
–
Cialis:
–
Total:
12,728,600,000 $-5.9%
Earnings release date:06 Feb. 25
Mounjaro:
3,530,100,000 $+13.4%
Zepbound:
1,907,300,000 $+51.6%
Trulicity:
1,250,200,000 $-3.9%
Jardiance:
1,198,400,000 $+74.6%
Other cardiometabolic health:
139,900,000 $+6.0%
Verzenio:
1,555,100,000 $+13.6%
Other oncology:
427,300,000 $+31.8%
Taltz:
952,000,000 $+8.2%
Other immunology:
77,300,000 $+39.8%
Neuroscience:
–
Other:
190,700,000 $-27.4%
Humalog:
619,900,000 $+16.0%
Humulin:
280,200,000 $+35.3%
Basaglar:
176,900,000 $+9.5%
Baqsimi:
3,400,000 $-74.6%
Alimta:
–
Cyramza:
258,400,000 $+9.5%
Erbitux:
175,000,000 $+15.1%
Tyvyt:
136,100,000 $-9.4%
Olumiant:
261,500,000 $+4.3%
Cymbalta:
–
Emgality:
249,800,000 $+23.1%
Zyprexa:
84,600,000 $+166.9%
Other neuroscience:
58,600,000 $-50.0%
COVID-19 antibodies:
–
Forteo:
–
Cialis:
–
Total:
13,532,700,000 $+18.3%
Earnings release date:30 Oct. 24
Mounjaro:
3,112,700,000 $+0.7%
Zepbound:
1,257,800,000 $+1.2%
Trulicity:
1,301,400,000 $+4.5%
Jardiance:
686,400,000 $-10.8%
Other cardiometabolic health:
132,000,000 $+12.8%
Verzenio:
1,369,300,000 $+2.8%
Other oncology:
324,300,000 $+8.4%
Taltz:
879,600,000 $+6.7%
Other immunology:
55,300,000 $+84.3%
Neuroscience:
–
Other:
262,800,000 $+26.6%
Humalog:
534,600,000 $-15.4%
Humulin:
207,100,000 $-7.4%
Basaglar:
161,600,000 $-10.6%
Baqsimi:
13,400,000 $+8.1%
Alimta:
–
Cyramza:
236,000,000 $-5.2%
Erbitux:
152,000,000 $-2.4%
Tyvyt:
150,200,000 $+22.1%
Olumiant:
250,800,000 $+10.1%
Cymbalta:
–
Emgality:
202,900,000 $+5.7%
Zyprexa:
31,700,000 $
Other neuroscience:
117,200,000 $-20.5%
COVID-19 antibodies:
–
Forteo:
–
Cialis:
–
Total:
11,439,100,000 $+1.2%
Earnings release date:08 Aug. 24
Mounjaro:
3,090,800,000 $+71.1%
Zepbound:
1,243,200,000 $+140.3%
Trulicity:
1,245,600,000 $-14.5%
Jardiance:
769,600,000 $+12.1%
Other cardiometabolic health:
117,000,000 $-5.5%
Verzenio:
1,331,900,000 $+26.8%
Other oncology:
299,100,000 $+11.4%
Taltz:
824,700,000 $+36.5%
Other immunology:
30,000,000 $+140.0%
Neuroscience:
–
Other:
207,600,000 $-14.2%
Humalog:
631,600,000 $+17.2%
Humulin:
223,600,000 $+8.4%
Basaglar:
180,800,000 $+14.7%
Baqsimi:
12,400,000 $
Alimta:
–
Cyramza:
248,900,000 $+8.3%
Erbitux:
155,800,000 $+7.7%
Tyvyt:
123,000,000 $+5.4%
Olumiant:
227,700,000 $+4.7%
Cymbalta:
–
Emgality:
192,000,000 $-14.9%
Zyprexa:
–
Other neuroscience:
147,500,000 $-9.7%
COVID-19 antibodies:
–
Forteo:
–
Cialis:
–
Total:
11,302,800,000 $+28.9%
Earnings release date:30 Apr. 24
Mounjaro:
1,806,500,000 $-18.1%
Zepbound:
517,400,000 $+194.3%
Trulicity:
1,456,300,000 $-12.8%
Jardiance:
686,500,000 $-14.0%
Other cardiometabolic health:
123,800,000 $+16.1%
Verzenio:
1,050,300,000 $-8.3%
Other oncology:
268,500,000 $-7.5%
Taltz:
604,100,000 $-23.0%
Other immunology:
12,500,000 $-83.6%
Neuroscience:
–
Other:
241,900,000 $+297.2%
Humalog:
538,700,000 $+46.9%
Humulin:
206,200,000 $+9.6%
Basaglar:
157,600,000 $-14.9%
Baqsimi:
–
Alimta:
–
Cyramza:
229,900,000 $-9.3%
Erbitux:
144,600,000 $-3.7%
Tyvyt:
116,700,000 $
Olumiant:
217,400,000 $-10.7%
Cymbalta:
–
Emgality:
225,700,000 $+21.3%
Zyprexa:
–
Other neuroscience:
163,400,000 $+544.0%
COVID-19 antibodies:
–
Forteo:
–
Cialis:
–
Total:
8,768,000,000 $-6.3%
Earnings release date:06 Feb. 24
Mounjaro:
2,205,600,000 $+56.5%
Zepbound:
175,800,000 $
Trulicity:
1,669,300,000 $-0.3%
Jardiance:
798,000,000 $+13.9%
Other cardiometabolic health:
106,600,000 $-24.9%
Verzenio:
1,145,400,000 $+10.1%
Other oncology:
290,200,000 $+5.4%
Taltz:
784,500,000 $+5.4%
Other immunology:
76,100,000 $+567.5%
Neuroscience:
–
Other:
60,900,000 $+42.0%
Humalog:
366,700,000 $-7.3%
Humulin:
188,100,000 $-9.0%
Basaglar:
185,200,000 $+3.1%
Baqsimi:
50,600,000 $+286.3%
Alimta:
44,900,000 $-16.1%
Cyramza:
253,500,000 $+13.1%
Erbitux:
150,200,000 $-2.4%
Tyvyt:
–
Olumiant:
243,500,000 $+5.2%
Cymbalta:
–
Emgality:
186,100,000 $+10.4%
Zyprexa:
213,400,000 $-85.6%
Other neuroscience:
-36,800,000 $-131.1%
COVID-19 antibodies:
–
Forteo:
116,500,000 $-20.4%
Cialis:
78,700,000 $-9.3%
Total:
9,353,000,000 $-1.5%
Earnings release date:02 Nov. 23
Mounjaro:
1,409,300,000 $+43.9%
Zepbound:
–
Trulicity:
1,673,600,000 $-7.7%
Jardiance:
700,800,000 $+4.9%
Other cardiometabolic health:
141,900,000 $+3.9%
Verzenio:
1,040,200,000 $+12.2%
Other oncology:
275,400,000 $+5.7%
Taltz:
744,200,000 $+5.7%
Other immunology:
11,400,000 $+100.0%
Neuroscience:
–
Other:
42,900,000 $-15.9%
Humalog:
395,400,000 $-10.2%
Humulin:
206,700,000 $+0.7%
Basaglar:
179,600,000 $+16.5%
Baqsimi:
13,100,000 $-97.9%
Alimta:
53,500,000 $-12.2%
Cyramza:
224,100,000 $-13.9%
Erbitux:
153,900,000 $-5.3%
Tyvyt:
–
Olumiant:
231,400,000 $+5.7%
Cymbalta:
–
Emgality:
168,500,000 $-0.5%
Zyprexa:
1,481,400,000 $
Other neuroscience:
118,200,000 $-45.8%
COVID-19 antibodies:
–
Forteo:
146,400,000 $-1.1%
Cialis:
86,800,000 $-24.9%
Total:
9,498,700,000 $+14.3%
Earnings release date:08 Aug. 23
Mounjaro:
979,700,000 $+72.3%
Zepbound:
–
Trulicity:
1,812,500,000 $-8.3%
Jardiance:
668,300,000 $+15.7%
Other cardiometabolic health:
136,600,000 $-5.9%
Verzenio:
926,800,000 $+23.4%
Other oncology:
260,500,000 $+44.6%
Taltz:
703,900,000 $+33.6%
Other immunology:
5,700,000 $-74.1%
Neuroscience:
–
Other:
51,000,000 $-3.4%
Humalog:
440,400,000 $-4.4%
Humulin:
205,300,000 $-18.5%
Basaglar:
154,200,000 $-26.3%
Baqsimi:
613,900,000 $
Alimta:
60,900,000 $+4.6%
Cyramza:
260,300,000 $+9.9%
Erbitux:
162,500,000 $+25.1%
Tyvyt:
–
Olumiant:
218,900,000 $-4.4%
Cymbalta:
–
Emgality:
169,300,000 $+9.7%
Zyprexa:
–
Other neuroscience:
217,900,000 $+5.7%
COVID-19 antibodies:
–
Forteo:
148,000,000 $+21.0%
Cialis:
115,600,000 $+15.3%
Total:
8,312,200,000 $+19.4%
Earnings release date:27 Apr. 23
Mounjaro:
568,500,000 $+92.6%
Zepbound:
–
Trulicity:
1,977,100,000 $+2.1%
Jardiance:
577,500,000 $-5.7%
Other cardiometabolic health:
145,100,000 $-2.1%
Verzenio:
750,900,000 $-7.1%
Other oncology:
180,200,000 $+58.9%
Taltz:
527,000,000 $-25.5%
Other immunology:
22,000,000 $+10.0%
Neuroscience:
–
Other:
52,800,000 $+4.1%
Humalog:
460,900,000 $-15.9%
Humulin:
252,000,000 $+7.7%
Basaglar:
209,300,000 $+3.8%
Baqsimi:
–
Alimta:
58,200,000 $-75.4%
Cyramza:
236,800,000 $-14.7%
Erbitux:
129,900,000 $-17.8%
Tyvyt:
–
Olumiant:
228,900,000 $+11.2%
Cymbalta:
–
Emgality:
154,300,000 $-12.1%
Zyprexa:
–
Other neuroscience:
206,200,000 $+191.7%
COVID-19 antibodies:
–
Forteo:
122,300,000 $-23.6%
Cialis:
100,300,000 $-6.2%
Total:
6,960,200,000 $-4.7%
Earnings release date:02 Feb. 23
Mounjaro:
295,200,000 $+57.6%
Zepbound:
–
Trulicity:
1,936,100,000 $+4.6%
Jardiance:
612,300,000 $+6.8%
Other cardiometabolic health:
148,200,000 $-14.5%
Verzenio:
807,900,000 $+30.8%
Other oncology:
113,400,000 $+10.7%
Taltz:
707,800,000 $+4.1%
Other immunology:
20,000,000 $+455.6%
Neuroscience:
–
Other:
50,700,000 $-23.9%
Humalog:
548,300,000 $+22.7%
Humulin:
234,000,000 $-1.8%
Basaglar:
201,700,000 $+4.5%
Baqsimi:
–
Alimta:
236,700,000 $+98.2%
Cyramza:
277,700,000 $+19.6%
Erbitux:
158,100,000 $+9.1%
Tyvyt:
57,400,000 $-25.3%
Olumiant:
205,800,000 $+12.5%
Cymbalta:
64,000,000 $+2.1%
Emgality:
175,600,000 $+4.2%
Zyprexa:
75,100,000 $-7.7%
Other neuroscience:
70,700,000 $+16.7%
COVID-19 antibodies:
38,100,000 $-90.1%
Forteo:
160,100,000 $-9.6%
Cialis:
106,900,000 $-7.6%
Total:
7,301,800,000 $+5.2%
Earnings release date:01 Nov. 22
Mounjaro:
187,300,000 $
Zepbound:
–
Trulicity:
1,850,400,000 $-3.2%
Jardiance:
573,300,000 $+24.4%
Other cardiometabolic health:
173,400,000 $+2.0%
Verzenio:
617,700,000 $+5.0%
Other oncology:
102,400,000 $-4.1%
Taltz:
679,900,000 $+12.2%
Other immunology:
3,600,000 $-10.0%
Neuroscience:
–
Other:
66,600,000 $-16.9%
Humalog:
447,000,000 $+0.0%
Humulin:
238,200,000 $-13.1%
Basaglar:
193,000,000 $+10.8%
Baqsimi:
–
Alimta:
119,400,000 $-47.6%
Cyramza:
232,100,000 $+0.3%
Erbitux:
144,900,000 $+2.9%
Tyvyt:
76,800,000 $+4.3%
Olumiant:
182,900,000 $-1.8%
Cymbalta:
62,700,000 $-17.0%
Emgality:
168,500,000 $+7.0%
Zyprexa:
81,400,000 $-6.8%
Other neuroscience:
60,600,000 $-12.9%
COVID-19 antibodies:
386,600,000 $+199.5%
Forteo:
177,100,000 $+27.9%
Cialis:
115,700,000 $-21.3%
Total:
6,941,500,000 $+7.0%
Earnings release date:04 Aug. 22
Mounjaro:
–
Zepbound:
–
Trulicity:
1,911,900,000 $
Jardiance:
461,000,000 $
Other cardiometabolic health:
170,000,000 $
Verzenio:
588,500,000 $
Other oncology:
106,800,000 $
Taltz:
606,200,000 $
Other immunology:
4,000,000 $
Neuroscience:
–
Other:
80,100,000 $
Humalog:
447,100,000 $
Humulin:
274,000,000 $
Basaglar:
174,200,000 $
Baqsimi:
–
Alimta:
227,700,000 $
Cyramza:
231,300,000 $
Erbitux:
140,800,000 $
Tyvyt:
73,600,000 $
Olumiant:
186,200,000 $
Cymbalta:
75,500,000 $
Emgality:
157,500,000 $
Zyprexa:
87,300,000 $
Other neuroscience:
69,600,000 $
COVID-19 antibodies:
129,100,000 $
Forteo:
138,500,000 $
Cialis:
147,000,000 $
Total:
6,487,900,000 $

Revenue by geographic location

Revenue by geographic locationTable view

Earnings release date
United States
Europe
China
Japan
Rest of world
Total
Earnings release date:30 Apr. 26
United States:
12,119,000,000 $-5.9%
Europe:
3,646,000,000 $+17.7%
China:
693,000,000 $+46.2%
Japan:
571,000,000 $-12.7%
Rest of world:
2,771,000,000 $+26.5%
Total:
19,800,000,000 $+2.6%
Earnings release date:04 Feb. 26
United States:
12,877,400,000 $+14.0%
Europe:
3,096,800,000 $-11.5%
China:
473,900,000 $-15.4%
Japan:
654,100,000 $+17.9%
Rest of world:
2,189,800,000 $+29.8%
Total:
19,292,000,000 $+9.6%
Earnings release date:30 Oct. 25
United States:
11,300,000,000 $+4.5%
Europe:
3,498,100,000 $+35.9%
China:
560,400,000 $+20.3%
Japan:
554,700,000 $+6.5%
Rest of world:
1,687,700,000 $+42.8%
Total:
17,600,900,000 $+13.1%
Earnings release date:07 Aug. 25
United States:
10,814,200,000 $+27.4%
Europe:
2,574,400,000 $+7.8%
China:
465,900,000 $+3.3%
Japan:
521,000,000 $+29.5%
Rest of world:
1,182,100,000 $+18.5%
Total:
15,557,600,000 $+22.2%
Earnings release date:01 May. 25
United States:
8,489,400,000 $-6.0%
Europe:
2,388,700,000 $-2.4%
China:
450,800,000 $+5.0%
Japan:
402,200,000 $-28.1%
Rest of world:
997,400,000 $-6.3%
Total:
12,728,500,000 $-5.9%
Earnings release date:06 Feb. 25
United States:
9,032,000,000 $+15.6%
Europe:
2,448,000,000 $+50.3%
China:
429,200,000 $-6.7%
Japan:
559,200,000 $+30.3%
Rest of world:
1,064,200,000 $-4.0%
Total:
13,532,600,000 $+18.3%
Earnings release date:30 Oct. 24
United States:
7,813,600,000 $-0.3%
Europe:
1,628,300,000 $+16.0%
China:
459,900,000 $+16.4%
Japan:
429,100,000 $-7.3%
Rest of world:
1,108,200,000 $-8.1%
Total:
11,439,100,000 $+1.2%
Earnings release date:08 Aug. 24
United States:
7,835,200,000 $+37.6%
Europe:
1,403,700,000 $-2.6%
China:
395,100,000 $+5.0%
Japan:
462,700,000 $+27.2%
Rest of world:
1,206,100,000 $+35.1%
Total:
11,302,800,000 $+28.9%
Earnings release date:30 Apr. 24
United States:
5,694,400,000 $-11.8%
Europe:
1,440,700,000 $+7.7%
China:
376,200,000 $-0.3%
Japan:
363,900,000 $-17.1%
Rest of world:
892,900,000 $+20.0%
Total:
8,768,100,000 $-6.3%
Earnings release date:06 Feb. 24
United States:
6,455,300,000 $+20.3%
Europe:
1,337,600,000 $-47.9%
China:
377,200,000 $-3.5%
Japan:
439,000,000 $+12.3%
Rest of world:
744,300,000 $-4.6%
Total:
9,353,400,000 $-1.5%
Earnings release date:02 Nov. 23
United States:
5,368,100,000 $-3.0%
Europe:
2,568,600,000 $+118.1%
China:
390,800,000 $-2.1%
Japan:
390,800,000 $-14.2%
Rest of world:
780,300,000 $+4.2%
Total:
9,498,600,000 $+14.3%
Earnings release date:08 Aug. 23
United States:
5,531,400,000 $+24.7%
Europe:
1,177,600,000 $+7.9%
China:
399,000,000 $+7.1%
Japan:
455,600,000 $+17.7%
Rest of world:
748,500,000 $+11.2%
Total:
8,312,100,000 $+19.4%
Earnings release date:27 Apr. 23
United States:
4,436,200,000 $-4.8%
Europe:
1,090,900,000 $+1.5%
China:
372,700,000 $+6.2%
Japan:
387,200,000 $-2.0%
Rest of world:
673,100,000 $-18.2%
Total:
6,960,100,000 $-4.7%
Earnings release date:02 Feb. 23
United States:
4,658,500,000 $+5.3%
Europe:
1,074,400,000 $+1.7%
China:
350,800,000 $+2.2%
Japan:
395,000,000 $-19.0%
Rest of world:
822,800,000 $+30.2%
Total:
7,301,500,000 $+5.2%
Earnings release date:01 Nov. 22
United States:
4,422,100,000 $+12.4%
Europe:
1,056,400,000 $-4.1%
China:
343,400,000 $-2.5%
Japan:
487,700,000 $+7.3%
Rest of world:
632,000,000 $-2.1%
Total:
6,941,600,000 $+7.0%
Earnings release date:04 Aug. 22
United States:
3,934,800,000 $
Europe:
1,101,100,000 $
China:
352,100,000 $
Japan:
454,400,000 $
Rest of world:
645,700,000 $
Total:
6,488,100,000 $

Operating expenses

Operating expensesTable view

Earnings release date
Cost of sales
Research and development
Marketing, selling and administrative
Acquired IPR&D
Asset impairment, restructuring and other special charges
Total
Earnings release date:30 Apr. 26
Cost of sales:
3,577,000,000 $+6.1%
Research and development:
3,510,000,000 $-7.7%
Marketing, selling and administrative:
2,934,000,000 $-6.3%
Acquired IPR&D:
584,000,000 $+10.4%
Asset impairment, restructuring and other special charges:
279,000,000 $+232.1%
Total:
10,884,000,000 $-0.3%
Earnings release date:04 Feb. 26
Cost of sales:
3,372,000,000 $+12.1%
Research and development:
3,802,000,000 $+9.7%
Marketing, selling and administrative:
3,132,000,000 $+14.3%
Acquired IPR&D:
529,000,000 $-19.3%
Asset impairment, restructuring and other special charges:
84,000,000 $-77.0%
Total:
10,919,000,000 $+6.7%
Earnings release date:30 Oct. 25
Cost of sales:
3,008,300,000 $+22.9%
Research and development:
3,465,700,000 $+3.9%
Marketing, selling and administrative:
2,740,700,000 $-0.4%
Acquired IPR&D:
655,700,000 $+326.3%
Asset impairment, restructuring and other special charges:
364,900,000 $
Total:
10,235,300,000 $+17.8%
Earnings release date:07 Aug. 25
Cost of sales:
2,447,800,000 $+10.1%
Research and development:
3,336,100,000 $+22.0%
Marketing, selling and administrative:
2,753,000,000 $+11.5%
Acquired IPR&D:
153,800,000 $-90.2%
Asset impairment, restructuring and other special charges:
–
Total:
8,690,700,000 $-3.8%
Earnings release date:01 May. 25
Cost of sales:
2,224,200,000 $-7.5%
Research and development:
2,733,700,000 $-9.6%
Marketing, selling and administrative:
2,468,800,000 $+1.8%
Acquired IPR&D:
1,571,700,000 $+730.7%
Asset impairment, restructuring and other special charges:
35,000,000 $-89.8%
Total:
9,033,400,000 $+7.7%
Earnings release date:06 Feb. 25
Cost of sales:
2,403,800,000 $+10.7%
Research and development:
3,022,500,000 $+10.5%
Marketing, selling and administrative:
2,424,500,000 $+15.5%
Acquired IPR&D:
189,200,000 $-93.3%
Asset impairment, restructuring and other special charges:
344,000,000 $+321.6%
Total:
8,384,000,000 $-15.4%
Earnings release date:30 Oct. 24
Cost of sales:
2,170,800,000 $+0.0%
Research and development:
2,734,100,000 $+0.8%
Marketing, selling and administrative:
2,099,800,000 $-0.8%
Acquired IPR&D:
2,826,400,000 $+1731.8%
Asset impairment, restructuring and other special charges:
81,600,000 $-81.2%
Total:
9,912,700,000 $+30.6%
Earnings release date:08 Aug. 24
Cost of sales:
2,170,200,000 $+29.7%
Research and development:
2,711,200,000 $+7.5%
Marketing, selling and administrative:
2,117,300,000 $+8.5%
Acquired IPR&D:
154,300,000 $+39.6%
Asset impairment, restructuring and other special charges:
435,000,000 $
Total:
7,588,000,000 $+21.2%
Earnings release date:30 Apr. 24
Cost of sales:
1,673,500,000 $-6.4%
Research and development:
2,522,800,000 $-1.6%
Marketing, selling and administrative:
1,952,200,000 $+1.4%
Acquired IPR&D:
110,500,000 $-82.3%
Asset impairment, restructuring and other special charges:
–
Total:
6,259,000,000 $-10.1%
Earnings release date:06 Feb. 24
Cost of sales:
1,788,000,000 $-3.9%
Research and development:
2,562,700,000 $+6.4%
Marketing, selling and administrative:
1,924,600,000 $+6.7%
Acquired IPR&D:
622,600,000 $-79.1%
Asset impairment, restructuring and other special charges:
67,700,000 $
Total:
6,965,600,000 $-23.0%
Earnings release date:02 Nov. 23
Cost of sales:
1,860,100,000 $+2.9%
Research and development:
2,409,100,000 $+2.2%
Marketing, selling and administrative:
1,803,900,000 $-6.3%
Acquired IPR&D:
2,975,100,000 $+2964.0%
Asset impairment, restructuring and other special charges:
–
Total:
9,048,200,000 $+46.3%
Earnings release date:08 Aug. 23
Cost of sales:
1,807,400,000 $+11.1%
Research and development:
2,356,500,000 $+18.7%
Marketing, selling and administrative:
1,925,400,000 $+10.1%
Acquired IPR&D:
97,100,000 $-7.5%
Asset impairment, restructuring and other special charges:
–
Total:
6,186,400,000 $+13.2%
Earnings release date:27 Apr. 23
Cost of sales:
1,626,700,000 $+5.1%
Research and development:
1,985,100,000 $-0.5%
Marketing, selling and administrative:
1,749,200,000 $+6.5%
Acquired IPR&D:
105,000,000 $-56.3%
Asset impairment, restructuring and other special charges:
–
Total:
5,466,000,000 $+0.0%
Earnings release date:02 Feb. 23
Cost of sales:
1,548,100,000 $-2.0%
Research and development:
1,995,900,000 $+10.7%
Marketing, selling and administrative:
1,643,200,000 $+1.8%
Acquired IPR&D:
240,100,000 $+284.8%
Asset impairment, restructuring and other special charges:
38,100,000 $-81.5%
Total:
5,465,400,000 $+3.8%
Earnings release date:01 Nov. 22
Cost of sales:
1,579,100,000 $+10.4%
Research and development:
1,802,900,000 $+1.2%
Marketing, selling and administrative:
1,614,200,000 $-0.7%
Acquired IPR&D:
62,400,000 $-85.8%
Asset impairment, restructuring and other special charges:
206,500,000 $
Total:
5,265,100,000 $-0.2%
Earnings release date:04 Aug. 22
Cost of sales:
1,430,500,000 $
Research and development:
1,781,900,000 $
Marketing, selling and administrative:
1,625,100,000 $
Acquired IPR&D:
440,400,000 $
Asset impairment, restructuring and other special charges:
–
Total:
5,277,900,000 $

Profitability

ProfitabilityTable view

Earnings release date
Net income (shareholders)
Free cash flow
Total
Earnings release date:30 Apr. 26
Net income (shareholders):
7,396,000,000 $+11.5%
Free cash flow:
3,007,000,000 $+343.6%
Total:
10,403,000,000 $+42.2%
Earnings release date:04 Feb. 26
Net income (shareholders):
6,636,000,000 $+18.9%
Free cash flow:
677,900,000 $-90.0%
Total:
7,313,900,000 $-40.7%
Earnings release date:30 Oct. 25
Net income (shareholders):
5,582,500,000 $-1.4%
Free cash flow:
6,748,200,000 $+385.6%
Total:
12,330,700,000 $+74.9%
Earnings release date:07 Aug. 25
Net income (shareholders):
5,660,500,000 $+105.1%
Free cash flow:
1,389,800,000 $+790.3%
Total:
7,050,300,000 $+141.8%
Earnings release date:01 May. 25
Net income (shareholders):
2,759,300,000 $-37.4%
Free cash flow:
156,100,000 $-84.0%
Total:
2,915,400,000 $-45.9%
Earnings release date:06 Feb. 25
Net income (shareholders):
4,409,800,000 $+354.5%
Free cash flow:
977,800,000 $-58.6%
Total:
5,387,600,000 $+61.7%
Earnings release date:30 Oct. 24
Net income (shareholders):
970,300,000 $-67.3%
Free cash flow:
2,361,200,000 $+878.1%
Total:
3,331,500,000 $+3.8%
Earnings release date:08 Aug. 24
Net income (shareholders):
2,967,000,000 $+32.3%
Free cash flow:
241,400,000 $+34.3%
Total:
3,208,400,000 $+32.4%
Earnings release date:30 Apr. 24
Net income (shareholders):
2,242,900,000 $+2.4%
Free cash flow:
179,700,000 $+113.0%
Total:
2,422,600,000 $+200.2%
Earnings release date:06 Feb. 24
Net income (shareholders):
2,189,600,000 $+3914.6%
Free cash flow:
-1,382,500,000 $-213.4%
Total:
807,100,000 $-30.5%
Earnings release date:02 Nov. 23
Net income (shareholders):
-57,400,000 $-103.3%
Free cash flow:
1,219,200,000 $+1246.9%
Total:
1,161,800,000 $-29.9%
Earnings release date:08 Aug. 23
Net income (shareholders):
1,763,200,000 $+31.1%
Free cash flow:
-106,300,000 $-110.0%
Total:
1,656,900,000 $-31.2%
Earnings release date:27 Apr. 23
Net income (shareholders):
1,344,900,000 $-30.6%
Free cash flow:
1,062,100,000 $-1.6%
Total:
2,407,000,000 $-20.2%
Earnings release date:02 Feb. 23
Net income (shareholders):
1,937,700,000 $+33.5%
Free cash flow:
1,079,000,000 $-31.2%
Total:
3,016,700,000 $-0.1%
Earnings release date:01 Nov. 22
Net income (shareholders):
1,451,700,000 $+52.4%
Free cash flow:
1,567,600,000 $+248.6%
Total:
3,019,300,000 $+115.3%
Earnings release date:04 Aug. 22
Net income (shareholders):
952,500,000 $
Free cash flow:
449,700,000 $
Total:
1,402,200,000 $

Profit margin in %

Profit margin in %Table view

Earnings release date
Profit margin (shareholders)
Profit margin (free cash flow)
Earnings release date:30 Apr. 26
Profit margin (shareholders):
37.35 %+3.0 pp
Profit margin (free cash flow):
15.19 %+11.7 pp
Earnings release date:04 Feb. 26
Profit margin (shareholders):
34.4 %+2.7 pp
Profit margin (free cash flow):
3.51 %-34.8 pp
Earnings release date:30 Oct. 25
Profit margin (shareholders):
31.72 %-4.7 pp
Profit margin (free cash flow):
38.34 %+29.4 pp
Earnings release date:07 Aug. 25
Profit margin (shareholders):
36.38 %+14.7 pp
Profit margin (free cash flow):
8.93 %+7.7 pp
Earnings release date:01 May. 25
Profit margin (shareholders):
21.68 %-10.9 pp
Profit margin (free cash flow):
1.23 %-6.0 pp
Earnings release date:06 Feb. 25
Profit margin (shareholders):
32.59 %+24.1 pp
Profit margin (free cash flow):
7.23 %-13.4 pp
Earnings release date:30 Oct. 24
Profit margin (shareholders):
8.48 %-17.8 pp
Profit margin (free cash flow):
20.64 %+18.5 pp
Earnings release date:08 Aug. 24
Profit margin (shareholders):
26.25 %+0.7 pp
Profit margin (free cash flow):
2.14 %+0.1 pp
Earnings release date:30 Apr. 24
Profit margin (shareholders):
25.58 %+2.2 pp
Profit margin (free cash flow):
2.05 %+16.8 pp
Earnings release date:06 Feb. 24
Profit margin (shareholders):
23.41 %+24.0 pp
Profit margin (free cash flow):
-14.78 %-27.6 pp
Earnings release date:02 Nov. 23
Profit margin (shareholders):
-0.6 %-21.8 pp
Profit margin (free cash flow):
12.84 %+14.1 pp
Earnings release date:08 Aug. 23
Profit margin (shareholders):
21.21 %+1.9 pp
Profit margin (free cash flow):
-1.28 %-16.5 pp
Earnings release date:27 Apr. 23
Profit margin (shareholders):
19.32 %-7.2 pp
Profit margin (free cash flow):
15.26 %+0.5 pp
Earnings release date:02 Feb. 23
Profit margin (shareholders):
26.54 %+5.6 pp
Profit margin (free cash flow):
14.78 %-7.8 pp
Earnings release date:01 Nov. 22
Profit margin (shareholders):
20.91 %+6.2 pp
Profit margin (free cash flow):
22.58 %+15.7 pp
Earnings release date:04 Aug. 22
Profit margin (shareholders):
14.68 %
Profit margin (free cash flow):
6.93 %